Wells Fargo & Company MN Buys 9,722 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Wells Fargo & Company MN raised its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 34.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,886 shares of the company's stock after purchasing an additional 9,722 shares during the quarter. Wells Fargo & Company MN owned approximately 0.06% of Twist Bioscience worth $1,761,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $34,000. US Bancorp DE grew its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience during the 3rd quarter valued at $95,000. Finally, KBC Group NV increased its holdings in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after buying an additional 1,226 shares in the last quarter.

Insider Activity

In other news, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the transaction, the director now directly owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 5,200 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the sale, the chief executive officer now owns 667,318 shares of the company's stock, valued at approximately $32,932,143.30. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,432 shares of company stock valued at $1,038,170. Insiders own 3.01% of the company's stock.

Twist Bioscience Stock Down 1.0 %

Shares of TWST traded down $0.40 during midday trading on Thursday, reaching $37.92. 197,610 shares of the company were exchanged, compared to its average volume of 977,465. The stock has a 50-day moving average price of $39.34 and a 200-day moving average price of $44.18. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -11.23 and a beta of 2.34. Twist Bioscience Co. has a 1-year low of $30.32 and a 1-year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same period last year, the business posted ($0.75) earnings per share. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. Research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Barclays lowered their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research report on Friday, March 28th. Finally, Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.